Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer

Fig. 3

Serum TAG-72 and CEA levels. Circulating sera levels of TAG-72 were measured by RIA in treated patients in: (a) Part A dose-escalation phase of IV CART72 cells in trial C-9701; (b) Part B expansion phase of trial C-9701; and (c) Intra-HA CART72 cells in trial C-9702. Circulating sera levels of CEA were measured in: (d) Part A of C-9701; (e) Part B of C-9701; and (f) C-9702. Seven of 8 evaluable patients treated with IV infusions of CART72 cells later demonstrated abrupt reductions (>80%) in serum TAG-72 levels (a, b). Two of 2 evaluable patients who received CART72 cells via HA infusion showed a marked decrease in measured serum TAG-72 at Week 8 (85% and 60%, respectively) (c). No associated reductions in sera CEA were observed, with an increase in the sera CEA levels over time observed in nine of 10 patients in trial C-9701 (d, e) and six of six patients in C-9702 (f). CEA, carcinoembryonic antigen; HA, hepatic artery; IV, intravenous

Back to article page